Showing promise in the field of weight management therapy, retatrutide presents a distinct approach. Different from many existing medications, retatrutide works as a twin agonist, at once targeting both GLP-like peptide-1 (GLP-1) and glucose-responsive insulinotropic polypeptide (GIP) binding sites. The concurrent stimulation encourages multiple he